The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The glob­al pan­dem­ic may have roiled economies, killed hun­dreds of thou­sands and throt­tled en­tire in­dus­tries, but the on­ly ef­fect it had on bio­phar­ma ven­ture in­vest­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.